drugset
Drugs / EG110A
last change Apr 2026 re-read 3 minutes ago

EG110A

Developed for
overactive bladder · spinal cord injury
Investigated by
EG 427 · Congressionally Directed Medical Research Programs

Trials 2

today NCT07227285 · Ph 1/2 NCT06596291 · Ph 1/2
2025202620272028202920302031
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07227285 Apr 2026 → Apr 2031 expected overactive bladder, spinal cord injury EG 427 Not yet recruiting No outcome recorded
Phase 1/2 NCT06596291 Jan 2025 → Jun 2027 expected overactive bladder, spinal cord injury EG 427 Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as EG110A ClinicalTrials.gov intervention name — accepted as the source's own label NCT07227285 ↗
1

NCT06596291 ↗
Route Other “multiple intradetrusor injections of EG110A” NCT06596291 ↗